"There is a window of opportunity early in the disease course where the benefits of KISUNLA are significant. We need to do everything possible to diagnose and treat patients at this early stage of the disease," said Tori Brown, the General Manager of Eli Lilly Australia and New Zealand.
Study reveals growing benefit of Lilly therapy for early symptomatic Alzheimer’s disease
August 1, 2025 Latest NewsBioPharmaNews of the Day
Latest Video
New Stories
-
The 'Dispatched' Podcast - Special episode
June 5, 2026 - - Podcast -
Opthea returns to ASX and works to restart eye therapy candidate
June 5, 2026 - - Latest News -
A clear disconnect between the public and private on 'Most Favored Nation' pricing
June 5, 2026 - - Latest News -
New blueprint charts a potential policy path forward on biosimilars
June 4, 2026 - - Latest News -
Study confirms pharmacist led care expands timely access to urinary tract infection treatment and contraception
June 4, 2026 - - BioPharma -
Officials talk down the prospect of MFN impact on the PBS
June 4, 2026 - - Latest News -
Novo Nordisk's Marie Krogh Prize returns and crosses the Tasman to back early career women in science
June 4, 2026 - - Latest News

